Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, no par value
-
Shares outstanding
-
109,272,143
-
Number of holders
-
56
-
Total 13F shares, excl. options
-
2,820,198
-
Shares change
-
+1,321,437
-
Total reported value, excl. options
-
$3,771,684
-
Value change
-
+$1,889,818
-
Number of buys
-
18
-
Number of sells
-
15
-
Price
-
$1.40
Institutional Holders of ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) as of Q3 2025
As of 30 Sep 2025 ONCOLYTICS BIOTECH INC - Common Stock, no par value (ONCY) had 64 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 2,820,198 shares of stock of the company.
Largest 10 holders included MORGAN STANLEY, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, SEEDS INVESTOR LLC, GOLDMAN SACHS GROUP INC, INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC, Quadrature Capital Ltd, FRANKLIN RESOURCES INC, ROYAL BANK OF CANADA, and GEODE CAPITAL MANAGEMENT, LLC.
This table shows 64 institutional shareholders of the security as of 30 Sep 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.